Maximizing the Outcomes of Breast Cancer Prevention

Cancer mortality in the United States has declined by about 1.5% per year since 1999. Patients with most of the common solid tumors have experienced decreased mortality risk over this period, including those with breast cancer, in whom mortality fell by 1.8% per year between 1998 and 2016. Although there is much to celebrate in these statistics, there is still a long way to go. Breast cancer remains the second leading cause of cancer death among US women, with an estimated 42  000 deaths in 2018. At this rate, it would take 80 years for breast cancer mortality to fall to less than 10 000 women per year.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research

Related Links:

Authors: Liang C, Li N, Cai Z, Liang R, Zheng X, Deng L, Feng L, Guo R, Wei B Abstract At present, cancer is the first cause of death for humans, but early detection and treatment can help improve prognoses and reduce mortality. However, further development of carrier-assistant drug delivery systems (DDSs) is retarded by the aspects such as the low drug-carrying capacity, carrier-induced toxicity and immunogenicity, complex synthesis manipulation. The development of nanoscale drug delivery systems (NDDS) have been rapidly developed to address these issues. In this article, we used PLGA-PEG with good biocompatibilit...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Garlic and ginger pills can delay the healing of skin wounds when breast cancer spreads, expert says.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news
Source: Vascular Health and Risk Management - Category: Cardiology Tags: Breast Cancer: Targets and Therapy Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Findings seen among postmenopausal breast cancer patients regardless of activity level prediagnosis
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Nursing, Oncology, Journal, Source Type: news
Publication date: Available online 13 November 2019Source: American Journal of Preventive MedicineAuthor(s): Ethan O. Cohen, Olena O. Weaver, Hilda H. Tso, Karen E. Gerlach, Jessica W.T. Leung
Source: American Journal of Preventive Medicine - Category: International Medicine & Public Health Source Type: research
Conclusions: Intra- and inter-provincial differences in the use of chemotherapy and acute care were observed. Understanding variations in care can help to identify gaps and opportunities for improvement and shared learnings. PMID: 31708656 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Conclusions: Use of the 21-gene rs assay could be a cost-effective strategy for Ontario patients with estrogen receptor-positive, her2-negative early bca and 1-3 positive lns. PMID: 31708649 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Might detection of mutations in CHEK2 be useful as a prognostic factor for patient response to treatment or potential for metastasis in breast cancer?Laboratory Medicine
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
In a new study, patients with HR+/HER2- early stage breast cancer completed 2 years of adjuvant palbociclib with a similar toxicity profile as that observed in the metastatic setting.Annals of Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Internal Medicine | Statistics | USA Health | Women